In general
For purposes of paragraph (1), the term “medically accepted indication” has the meaning given that term—
(i)#
in the case of a covered part D drug used in an anticancer chemotherapeutic regimen, in section 1395x(t)(2)(B) of this title , except that in applying such section—
(I) “prescription drug plan or MA–PD plan” shall be substituted for “carrier” each place it appears; and
(II) subject to subparagraph (B), the compendia described in section 1396r–8(g)(1)(B)(i)(III) of this title shall be included in the list of compendia described in clause (ii)(I) section 1395x(t)(2)(B) of this title ; and
(i)(I)#
“prescription drug plan or MA–PD plan” shall be substituted for “carrier” each place it appears; and
(i)(II)#
subject to subparagraph (B), the compendia described in section 1396r–8(g)(1)(B)(i)(III) of this title shall be included in the list of compendia described in clause (ii)(I) section 1395x(t)(2)(B) of this title ; and
(ii)#
in the case of any other covered part D drug, in section 1396r–8(k)(6) of this title .